A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 2,410,400 shares of ALLO stock, worth $4.51 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
2,410,400
Previous 2,242,500 7.49%
Holding current value
$4.51 Million
Previous $5.23 Million 29.17%
% of portfolio
0.02%
Previous 0.01%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.08 - $3.5 $349,232 - $587,650
167,900 Added 7.49%
2,410,400 $6.75 Million
Q2 2024

Aug 14, 2024

BUY
$2.23 - $4.38 $2.03 Million - $3.99 Million
911,400 Added 68.47%
2,242,500 $5.23 Million
Q1 2024

May 15, 2024

BUY
$2.92 - $5.63 $155,928 - $300,642
53,400 Added 4.18%
1,331,100 $5.95 Million
Q4 2023

Feb 14, 2024

BUY
$2.28 - $3.5 $685,139 - $1.05 Million
300,500 Added 30.75%
1,277,700 $4.1 Million
Q3 2023

Nov 14, 2023

SELL
$3.17 - $5.96 $752,875 - $1.42 Million
-237,500 Reduced 19.55%
977,200 $3.1 Million
Q2 2023

Aug 14, 2023

SELL
$4.53 - $6.74 $362,853 - $539,874
-80,100 Reduced 6.19%
1,214,700 $6.04 Million
Q1 2023

May 15, 2023

BUY
$4.92 - $8.21 $1.65 Million - $2.75 Million
334,400 Added 34.82%
1,294,800 $6.4 Million
Q4 2022

Feb 14, 2023

BUY
$5.62 - $11.11 $4.15 Million - $8.2 Million
737,900 Added 331.64%
960,400 $6.04 Million
Q3 2022

Nov 14, 2022

BUY
$10.32 - $17.28 $928,800 - $1.56 Million
90,000 Added 67.92%
222,500 $2.4 Million
Q2 2022

Aug 15, 2022

SELL
$6.78 - $12.28 $678,000 - $1.23 Million
-100,000 Reduced 43.01%
132,500 $1.51 Million
Q1 2022

May 16, 2022

BUY
$7.65 - $15.29 $1.78 Million - $3.55 Million
232,500 New
232,500 $2.12 Million
Q3 2021

Nov 15, 2021

SELL
$21.01 - $27.64 $1.42 Million - $1.87 Million
-67,800 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$23.49 - $35.8 $8.13 Million - $12.4 Million
-346,300 Reduced 83.63%
67,800 $1.77 Million
Q1 2021

May 17, 2021

BUY
$25.79 - $39.02 $1.61 Million - $2.43 Million
62,300 Added 17.71%
414,100 $14.6 Million
Q4 2020

Feb 16, 2021

BUY
$25.24 - $43.45 $360,932 - $621,335
14,300 Added 4.24%
351,800 $8.88 Million
Q3 2020

Nov 16, 2020

BUY
$32.38 - $44.96 $9.89 Million - $13.7 Million
305,300 Added 948.14%
337,500 $12.7 Million
Q2 2020

Aug 14, 2020

BUY
$18.39 - $54.04 $592,158 - $1.74 Million
32,200 New
32,200 $1.38 Million

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $269M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.